Rezolute Inc Market Cap ($381.32 Million)
Market Cap & Net Worth: Rezolute Inc (RZLT)
Rezolute Inc market cap. Rezolute Inc (NASDAQ:RZLT) has a market capitalization of $381.32 Million ($381.32 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13369 globally and #3264 in its home market, demonstrating a -3.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rezolute Inc's stock price $3.96 by its total outstanding shares 96292331 (96.29 Million). Also see RZLT cash flow conversion for how efficiently the company converts equity into cash flow.
Rezolute Inc Market Cap History (2015–2026)
Rezolute Inc market cap history from 2015 to 2026. Data shows change from $7.03 Billion to $381.32 Million (-22.09% CAGR). Check Rezolute Inc stock quote for real-time trading data and today's change.
Index Memberships
Rezolute Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #363 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1313 of 3165 |
Weight: Rezolute Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rezolute Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rezolute Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RZLT shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RZLT by Market Capitalization
Companies near Rezolute Inc in the global market cap rankings as of November 5, 2026. Also see balance sheet size of Rezolute Inc for a full breakdown of the balance sheet.
Key companies related to Rezolute Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Rezolute Inc (2015–2026)
Market capitalization of Rezolute Inc from 2015 to today. Between 2015 and today, Rezolute Inc's market cap moved from $7.03 Billion to $ 381.32 Million, with a yearly change of -22.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $381.32 Million | +67.80% |
| 2025 | $227.25 Million | -51.84% |
| 2024 | $471.83 Million | +393.70% |
| 2023 | $95.57 Million | -52.05% |
| 2022 | $199.33 Million | -56.69% |
| 2021 | $460.28 Million | -60.13% |
| 2020 | $1.15 Billion | +108.52% |
| 2019 | $553.68 Million | +27.78% |
| 2018 | $433.32 Million | -89.83% |
| 2017 | $4.26 Billion | -11.50% |
| 2016 | $4.81 Billion | -31.51% |
| 2015 | $7.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Rezolute Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $381.32 Million USD |
| MoneyControl | $381.32 Million USD |
| MarketWatch | $381.32 Million USD |
| marketcap.company | $381.32 Million USD |
| Reuters | $381.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more